Morgan Stanley Downgrades DOC to Hold, Sets $22 Price Target
Morgan Stanley analyst Richard Hill downgraded DOC to hold with a $22 target, a 6.33% upside from the current price.
Key Points
- Morgan Stanley downgraded DOC to a hold rating with a $22 price target on June 11, 2026.
- Morgan Stanley's $22 price target implies 6.33% upside from Healthpeak Properties, Inc.'s ($DOC) current $20.69 share price.
- Shares of DOC traded near $20.69, with recent insider buying and selling activity noted.
- Other analysts including Wells Fargo and Scotiabank maintain a hold rating on DOC.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 11, 2026, Morgan Stanley analyst Richard Hill downgraded DOC to a hold rating and set a price target of $22. This change reflects a more cautious outlook on the company's stock.
Other Institutional Activity in DOC
Several other institutional investors have adjusted their positions in DOC. BlackRock, Inc. slightly reduced its holdings by 182,068 shares, ending with 73,360,519 shares valued at about $1.21 billion. Vanguard Portfolio Management LLC established a new position with 58,125,899 shares worth approximately $955 million. State Street Corp trimmed its stake by 872,866 shares, leaving it with 48,500,600 shares valued at roughly $797 million. Meanwhile, JPMorgan Chase & Co significantly increased its holdings by 14,056,729 shares, totaling 44,731,541 shares worth around $740 million.
Healthpeak Properties, Inc. Stock Down 1.3%
Shares of DOC traded near $20.69. The stock has been under the spotlight with significant institutional movements and analyst ratings adjustments.
$DOC price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Healthpeak Properties, Inc.
Recent insider transactions at DOC include several notable movements. On May 29, 2026, EVP and Treasurer Ankit Patadia bought 1,358 shares at $15.46 per share and sold 94 shares at $19.15. Chief Financial Officer Kelvin Moses also purchased 937 shares at $15.46. Additionally, President and CEO Scott Brinker sold 114 shares at $19.15.
Analysts Set New Price Targets
On June 11, 2026, Morgan Stanley downgraded DOC to a hold rating with a $22 price target. Previously, on June 1, Wells Fargo maintained a hold rating with a $20 target, and on May 27, Scotiabank also maintained a hold with a $21 target. These ratings reflect a generally cautious stance among analysts.
About DOC
DOC is a company operating in the healthcare sector, providing services and solutions related to healthcare real estate. The company is known for its strategic management of healthcare facilities, offering a range of services to healthcare providers. DOC is headquartered in the United States and focuses on creating value through its real estate investments.
Bottom Line
Morgan Stanley's downgrade of DOC to a hold rating with a $22 target highlights a shift in sentiment. The stock's recent trading activity, along with insider transactions, provides additional context for investors. As always, remember that these analyst ratings and institutional moves are backward-looking and may not reflect the current market conditions.
Get Healthpeak Properties, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DOC, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.